News

News 24.10.2024 Zurich, Switzerland - 23.10.2024 Neurimmune today announced that the translational PK/PD model relating to the human antibody ALXN2220 (formerly NI006) have been published in the current issue of Clinical Pharmacology & Therapeutics. The manuscript “Prediction of cardiac ATTR depletion by NI006 (ALXN2220) using mechanistic PK/PD modeling” describes the mechanistic pharmacokinetic and pharmacodynamic...

News 23.10.2024 Using a new method, researchers at ETH Zurich can measure alterations in the social network of proteins in cells. This work lays the foundation for the development of new drugs to treat diseases such as cancer and Alzheimer’s. Inside cells, it's like in a packed dance club: hundreds are partying. Some...

News 22.10.2024 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass. and PARIS, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, and Orano Med, a clinical-stage radiopharmaceutical...

News 22.10.2024 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) --  Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced...

News 18.10.2024 Saint Herblain (France) and Schlieren (Zurich), October 16, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast...